See more : PT Telefast Indonesia Tbk (TFAS.JK) Income Statement Analysis – Financial Results
Complete financial analysis of Lin BioScience, Inc. (6696.TWO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Lin BioScience, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Federal National Mortgage Association (FNMAT) Income Statement Analysis – Financial Results
- Addtech AB (publ.) (0QI7.L) Income Statement Analysis – Financial Results
- Crest Ventures Limited (CREST.BO) Income Statement Analysis – Financial Results
- Sino ICT Holdings Limited (0365.HK) Income Statement Analysis – Financial Results
- First Republic Bank (FRC-PI) Income Statement Analysis – Financial Results
Lin BioScience, Inc. (6696.TWO)
About Lin BioScience, Inc.
Lin BioScience, Inc., a drug development company, develops therapies for oncology, ophthalmology, and metabolic diseases. Its product pipeline includes LBS-008, an oral therapy for dry age-related macular degeneration (Dry AMD)and stargardt diseases (STGD1), which is under Phase 3 clinical trial to evaluate safety and efficacy in adolescent STGD1 and under phase 2 or phase 3 clinical trial to evaluate safety and efficacy in Dry AMD; LBS-007, a natural non-ATP CDC7 inhibitor for the treatment of cancers; LBS-002, an anti-tubulin to treat primary and metastatic brain tumors; and LBS-009, an oral therapy for the treatment of non-alcoholic fatty liver disease and type 2 diabetes. The company is headquartered in Taipei, Taiwan.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 17.93M | 11.16M | 4.39M | 4.08M | 4.31M |
| Gross Profit | -17.93M | -11.16M | -4.39M | -4.08M | -4.31M |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 854.07M | 320.87M | 244.76M | 145.01M | 193.35M |
| General & Administrative | 240.49M | 120.00M | 89.64M | 49.07M | 0.00 |
| Selling & Marketing | 2.26M | 4.25M | 3.88M | 2.92M | 0.00 |
| SG&A | 242.75M | 124.26M | 93.52M | 51.99M | 40.56M |
| Other Expenses | 0.00 | -33.06M | -152.26M | 21.96M | 0.00 |
| Operating Expenses | 1.10B | 445.13M | 338.28M | 196.99M | 233.91M |
| Cost & Expenses | 1.10B | 445.13M | 338.28M | 196.99M | 238.22M |
| Interest Income | 4.49M | 1.19M | 193.00K | 502.00K | 0.00 |
| Interest Expense | 1.21M | 875.00K | 71.00K | 261.00K | 0.00 |
| Depreciation & Amortization | 17.93M | 11.16M | 4.39M | 4.08M | 4.31M |
| EBITDA | -1.07B | -465.84M | -485.95M | -170.46M | -235.36M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -1.10B | -477.00M | -490.34M | -174.54M | -238.22M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 6.29M | -32.74M | -152.14M | 22.20M | -1.81M |
| Income Before Tax | -1.09B | -477.87M | -490.41M | -174.80M | -240.03M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -29.72M | -18.44M | -9.51M | -22.95M | -4.78M |
| Net Income | -687.19M | -313.52M | -434.70M | -151.84M | -235.26M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -9.29 | -4.37 | -6.23 | -2.39 | -3.87 |
| EPS Diluted | -9.29 | -4.37 | -6.23 | -2.39 | -3.87 |
| Weighted Avg Shares Out | 73.99M | 71.74M | 69.80M | 63.54M | 60.85M |
| Weighted Avg Shares Out (Dil) | 73.99M | 71.74M | 69.80M | 63.54M | 60.85M |
Source: https://incomestatements.info
Category: Stock Reports